— Know what they know.
Not Investment Advice

OLMA NASDAQ

Olema Pharmaceuticals, Inc.
1W: +1.7% 1M: -13.4% 3M: -41.6% YTD: -44.4% 1Y: +176.8% 3Y: +121.8% 5Y: -44.0%
$13.68
-0.38 (-2.70%)
 
Weekly Expected Move ±5.8%
$12 $13 $14 $14 $15
NASDAQ · Healthcare · Biotechnology · Alpha Radar Sell · Power 29 · $1.2B mcap · 75M float · 1.98% daily turnover · Short 53% of daily vol

Balance Sheet Trends

Total Assets
$533M +18.3% ▲
5Y CAGR: +9.3%
Total Liabilities
$55M +30.6% ▲
5Y CAGR: +64.3%
Shareholders Equity
$479M +17.0% ▲
5Y CAGR: +7.2%
Cash & Investments
$505M +16.4% ▲
5Y CAGR: +8.3%
Total Debt
$1M -16.5% ▼
Net Debt
-$47M +65.9% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$14M$24M$69M$139M$48M
Short-Term Investments$273M$181M$193M$295M$457M
Cash & ST Investments$287M$204M$262M$434M$505M
Net Receivables$130K$319K$673K$2M$4M
Inventory$0$0$0$0$0
Other Current Assets$0$2M$2M$366K$6M
Total Current Assets$291M$209M$267M$438M$515M
Property, Plant & Equip.$5M$4M$3M$2M$1M
Goodwill & Intangibles$0$0$0$683K$0
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$540K$3M$7M$10M$17M
Total Non-Current Assets$5M$7M$10M$13M$18M
Total Assets$296M$216M$277M$451M$533M
— Liabilities —
Accounts Payable$23K$374K$3M$4M$9M
Short-Term Debt$0$0$0$0$1M
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$4M$5M$5M$0$32M
Total Current Liabilities$9M$17M$22M$42M$52M
Long-Term Debt$0$0$0$0$69K
Other Non-Current Liab.$0$0$0$0$3M
Total Non-Current Liabilities$2M$2M$1M$257K$3M
Total Liabilities$11M$18M$23M$42M$55M
— Equity —
Common Stock$3K$3K$4K$6K$8K
Retained Earnings-$104M-$209M-$306M-$435M-$598M
Accumulated OCI-$149K-$2M$347K$143K$621K
Total Stockholders Equity$285M$198M$254M$409M$479M
Total Liabilities & Equity$296M$216M$277M$451M$533M
— Key Metrics —
Total Debt$3M$3M$2M$1M$1M
Net Debt-$11M-$21M-$66M-$138M-$47M
Total Investments$273M$181M$193M$295M$457M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms